358 participants
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-06-04
- Start Date:
- 2021-07-22
- Completion:
- 2023-04-21
Conditions
- Ovarian Cancer
Interventions
- DRUG